［1］Mai Q，Mai X，Huang X，et al.Imprinting status in two human parthenogenetic embryonic stem cell lines：Analysis of 63 imprinted gene expression levels in undifferentiated and early differentiated stages［J］.Stem Cells Dev，2018，27(6)：430-439.
[2]Hoekstra AS，Addie RD，Ras C，et al.Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas：SLC22A18 and CDKN1C are candidate tumour modifiers［J］.Hum Mol Genet，2016，25(17)：3715-3728.
[3]Altinoz MA，Elmaci I，Ince B，et al.Hemoglobins，hemorphins，and 11p15.5 chromosomal region in cancer biology and immunity with special emphasis for brain tumors［J］.J Neurol Surg A Cent Eur Neurosurg，2016，77(3)：247-257.
[4]Yang Biao，Chu Shenghua，Ma Yanbin.Overcoming acquired resistance by SLC22A18 silencing in human glioma［J］.Modern Oncology，2018，26(7)：981-984.［杨标，楚胜华，马延斌.沉默Bcl-XL逆转人胶质瘤获得性SLC22A18的耐药［J］.现代肿瘤医学，2018，26(7)：981-984.］
[5]Yang Biao，Ma Yanbin，Chu Shenghua.Effects of different chemotherapeutic drugs on reversing the acquired drug resistance to SLC22A18 gene in glioma U251 cells［J］.Modern Oncology，2018，26(17)：2670-2673.［杨标，马延斌，楚胜华.不同化疗药物对胶质瘤获得性SLC22A18基因耐药的逆转作用［J］.现代肿瘤医学，2018，26(17)：2670-2673.］
[6]Zavala-Vega S，Castro-Escarpulli G，Hernández-Santos H，et al.An overview of the infection of CMV，HSV 1/2 and EBV in Mexican patients with glioblastoma multiforme［J］.Pathol Res Pract，2017，213(3)：271-276.
[7]Eftimov T，Enchev Y，Tsekov I，et al.JC polyomavirus in the aetiology and pathophysiology of glial tumours［J］.Neurosurg Rev，2016，39(1)：47-53.
[8]Jiang B，Li M，Ji F，et al.MicroRNA-219 exerts a tumor suppressive role in glioma via targeting Sal-like protein 4［J］.Exp Ther Med，2017，14(6)：6213-6221.
[9]Xiao B，Li J，Fan Y，et al.Downregulation of SYT7 inhibits glioblastoma growth by promoting cellular apoptosis［J］.Mol Med Rep，2017，16(6)：9017-9022.
[10]Yu T，Wang Y，Hu Q，et al.The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells［J］.Oncotarget，2017，8(58)：98348-98359.
[11]Yuan ZS，Cao Y，Li ZY.IGFBP2 induces SPRY1 expression via NF-κB signaling pathway in glioblastoma multiforme (GBM)［J］.Eur Rev Med Pharmacol Sci，2017，21(22)：5072-5080.
[12]Dugo M，Nicolini G，Tragni G，et al.A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification［J］.Oncotarget，2015，6(7)：5118-5133.
[13]DiNardo CD，Stein EM，de Botton S，et al.Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML［J］.N Engl J Med，2018，378(25)：2386-2398.
[14]Maldonado MDM，Dharmawardhane S.Targeting rac and Cdc42 GTPases in cancer［J］.Cancer Res，2018，78(12)：3101-3111.
[15]Wang YT，Yuan B，Chen HD，et al.Acquired resistance of phosphatase and tensin homolog-deficient cells to poly (ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression［J］.Cancer Sci，2018，109(3)：821-831.